Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1

The remarkable heterogeneity of glioblastoma, across patients and over time, is one of the main challenges in precision diagnostics and treatment planning. Non-invasive in vivo characterization of this heterogeneity using imaging could assist in understanding disease subtypes, as well as in risk-str...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2018-03, Vol.8 (1), p.5087-12, Article 5087
Main Authors: Rathore, Saima, Akbari, Hamed, Rozycki, Martin, Abdullah, Kalil G, Nasrallah, MacLean P, Binder, Zev A, Davuluri, Ramana V, Lustig, Robert A, Dahmane, Nadia, Bilello, Michel, O'Rourke, Donald M, Davatzikos, Christos
Format: Article
Language:English
Subjects:
Brain - diagnostic imaging
Brain cancer
Brain Neoplasms - diagnostic imaging
DNA methyltransferase
Edema
Epidermal growth factor
ErbB Receptors - analysis
Female
Glioblastoma
Glioblastoma - diagnostic imaging
Humans
Isocitrate dehydrogenase
Isocitrate Dehydrogenase - analysis
Magnetic resonance imaging
Magnetic Resonance Imaging - methods
Male
Medical prognosis
Medicine
Methylguanine
Neuroimaging
O-Methylguanine-DNA Methyltransferase - analysis
Patients
Prognosis
Radiomics
Reproducibility
Survival Analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The remarkable heterogeneity of glioblastoma, across patients and over time, is one of the main challenges in precision diagnostics and treatment planning. Non-invasive in vivo characterization of this heterogeneity using imaging could assist in understanding disease subtypes, as well as in risk-stratification and treatment planning of glioblastoma. The current study leveraged advanced imaging analytics and radiomic approaches applied to multi-parametric MRI of de novo glioblastoma patients (n = 208 discovery, n = 53 replication), and discovered three distinct and reproducible imaging subtypes of glioblastoma, with differential clinical outcome and underlying molecular characteristics, including isocitrate dehydrogenase-1 (IDH1), O -methylguanine-DNA methyltransferase, epidermal growth factor receptor variant III (EGFRvIII), and transcriptomic subtype composition. The subtypes provided risk-stratification substantially beyond that provided by WHO classifications. Within IDH1-wildtype tumors, our subtypes revealed different survival (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-22739-2